![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Medtronic Begins U.S. Study of Resolute Onyx Drug-Eluting Stent
Medtronic Begins U.S. Study of Resolute Onyx Drug-Eluting Stent
![](https://www.fdanews.com/ext/resources/test/Device_Images3/Medtronic.gif?t=1433878552&width=430)
Medtronic has launched a U.S. trial of its Resolute Onyx drug-eluting stent. The first phase of the study will evaluate the device’s effectiveness in of patients with coronary artery disease who have small vessels requiring a 2 mm stent. Other stent sizes will be studied separately, the devicemaker said Thursday.
The Resolute Onyx DES features CoreWire technology, which gives it a dense metal core surrounded by a cobalt alloy. CoreWire technology is a method of stent manufacturing that molds one single strand of wire into a sinusoidal wave, enabling a continuous range of motion, the Irish devicemaker said. This also allows for greater visibility during the procedure, but with thinner struts, the firm added.
The stent was CE-marked in November 2014. — Kellen Owings
Upcoming Events
-
21Oct